CION Ameerpet
After induction brings follicular lymphoma into remission, maintenance therapy — usually a gentle anti-CD20 antibody given at spaced intervals — aims to hold the disease back for longer. This guide explains what it is, how long it lasts and who it is for.
Maintenance therapy is a lower-intensity treatment given after the main course of treatment — called induction — has already brought follicular lymphoma into remission. Its job is not to attack a large, active tumour, but to keep the disease quiet for as long as possible. Think of induction as putting out the fire and maintenance as keeping the embers from re-igniting.
Follicular lymphoma is an indolent — slow-growing — form of non-Hodgkin lymphoma. It tends to behave as a long-term, remitting-and-relapsing condition rather than something removed once and forgotten. That is exactly why the idea of lymphoma maintenance treatment exists: by continuing a gentle, targeted therapy at spaced intervals, the goal is to lengthen the remission you have already achieved.
In follicular lymphoma, follicular maintenance is built around an anti-CD20 monoclonal antibody — a form of targeted immunotherapy. To understand how these antibodies work, see our page on immunotherapy & monoclonal antibodies for lymphoma. For the wider treatment picture, visit the lymphoma hub or our Lymphoma Treatment in Hyderabad page.
Both NCCN and ESMO guidelines describe maintenance with an anti-CD20 monoclonal antibody — typically given every two to three months for about two years — as an option after a good response to induction in follicular lymphoma. It is offered to prolong remission, not because the disease is still active; many people continue their normal daily routine throughout. (Source: NCCN Guidelines for B-cell Lymphomas & ESMO Clinical Practice Guidelines for follicular lymphoma.)
Because follicular lymphoma is slow-growing and long-lived, the treatment philosophy is different from fast-growing lymphomas. The aim is durable control with the least burden.
The central purpose of follicular maintenance is to extend the remission reached with induction — delaying the point at which the lymphoma becomes active again and treatment is needed once more.
Maintenance uses an anti-CD20 antibody that homes in on the CD20 marker carried by B-cell lymphoma cells, rather than broad chemotherapy — so it is usually far better tolerated over the long run.
Maintenance is only relevant after induction. Many people with low-burden disease are instead safely watched. The right path is a considered decision, not automatic — read more on the lymphoma hub.
Whether to start maintenance, and for how long, is discussed by CION's multidisciplinary team — weighing your response to induction, risk features and your own preferences.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just finished induction, weighing whether follicular maintenance is worth it, or want a second opinion on your plan? CION's haematology team is here to help you decide.
Maintenance therapy is deliberately spaced out and low in intensity. The details are individualised, but the general shape of a course looks like this:
Follicular maintenance uses an anti-CD20 monoclonal antibody. This is an immunotherapy, not conventional chemotherapy: it binds to the CD20 marker on the surface of B-cell lymphoma cells and flags them for the immune system. We describe therapy by drug class and mechanism on this page rather than by molecule or brand name — for the exact regimen names, your treating haematologist will explain them, and you can read more on our Lymphoma Treatment in Hyderabad page or our overview of targeted therapy for lymphoma.
Typically the antibody is given as an infusion once every two to three months for around two years after a good response to induction, following NCCN and ESMO guidance. The precise interval and total length are tailored to you. Some people are advised a shorter course; some do not need maintenance at all.
Each maintenance visit is usually a straightforward outpatient infusion with monitoring — most people return to normal activity the same or next day. If you would like a walkthrough, read what to expect during a chemo / immunotherapy infusion. For people who need repeated infusions, we can also explain chemo ports and central lines. CION delivers these infusions and all monitoring directly.
Because it is antibody-based rather than intensive chemotherapy, follicular maintenance is generally well tolerated. The main things the team watches for are:
Compared with the side effects that can come with induction chemotherapy, the maintenance phase is usually much lighter — but any fever or new infection should be reported promptly. For more on managing treatment side effects generally, see managing lymphoma chemotherapy side effects.
It helps to be clear-eyed about the goal. Follicular lymphoma is usually managed as a long-term condition, and honest expectation-setting is part of good care.
Published trials show that maintenance with an anti-CD20 antibody can meaningfully prolong the time in remission (progression-free time) after induction. The impact on overall survival is less clear-cut, and the benefit must be balanced against the inconvenience and side effects of continuing treatment. Figures vary by individual, and follicular lymphoma outcomes are generally favourable compared with many other cancers — but no treatment is described as a guaranteed cure.
Because follicular lymphoma relapses and remits, some people see it return during or after maintenance. There is a clear relapsed or refractory pathway: the team reconfirms the disease and chooses the next step, which may include a different systemic therapy, involved-site radiation, or referral for advanced cellular treatments. CION coordinates CAR T-cell therapy and stem cell transplant — including autologous and allogeneic (donor) transplant — through accredited partner facilities, while delivering chemotherapy, immunotherapy, targeted therapy and radiation directly.
Research in follicular lymphoma is active, and other antibody-based approaches such as bispecific antibodies are being studied in the relapsed setting. If you are interested in research, ask about clinical trials for lymphoma at your consultation.
Whether to start follicular maintenance — and for how long — is a finely balanced decision, and a second opinion is especially useful when:
CION offers a dedicated, free written second-opinion service, and you can also see our best lymphoma doctors in Hyderabad and best lymphoma hospital in Hyderabad pages. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's haematology team on your follicular lymphoma plan — including whether maintenance or continued monitoring makes more sense for you.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Maintenance therapy is a lower-intensity treatment given after the main (induction) treatment has brought follicular lymphoma into remission. Its goal is to keep the disease in check for longer, not to attack a large, active tumour. In follicular lymphoma the maintenance approach most commonly uses an anti-CD20 monoclonal antibody — an immunotherapy given at spaced intervals over roughly two years. Because it targets a marker (CD20) on the lymphoma cells rather than dividing cells in general, it is usually far gentler than induction chemotherapy. Whether maintenance is right for you depends on how you responded to induction and your overall risk. Every plan at CION is set by a multidisciplinary tumour board.
For follicular lymphoma, maintenance with an anti-CD20 monoclonal antibody is typically given at fixed intervals — commonly once every two to three months — for about two years after a good response to induction, in line with NCCN and ESMO guidance. The exact schedule and duration are individualised. Some people are advised a shorter course, and others may not need maintenance at all if watch-and-wait remains appropriate. Duration is a decision your haematologist makes with you, weighing the benefit of a longer remission against the inconvenience and side effects of continued treatment. Timelines vary by individual and are reviewed at each visit.
No treatment is described as a guaranteed cure for follicular lymphoma, and maintenance therapy is not a cure either. Follicular lymphoma is usually an indolent (slow-growing) disease that tends to remit and relapse over many years. The aim of follicular maintenance is to lengthen the remission achieved by induction and delay the time until the disease becomes active again. Published trials show maintenance can prolong progression-free time, though the effect on overall survival is less clear-cut and figures vary by individual. Because it treats a condition that is managed over the long term rather than eradicated, honest expectation-setting matters — something CION's team discusses openly at every review.
Follicular maintenance is built around an anti-CD20 monoclonal antibody — a type of targeted immunotherapy that locks onto the CD20 protein carried on the surface of B-cell lymphoma cells and flags them for the immune system. It is an antibody, not conventional chemotherapy, which is why the side-effect profile during maintenance is generally milder. We deliberately describe therapy by drug class and mechanism here rather than by brand or molecule name; for specific regimens and their names, see our Lymphoma Treatment in Hyderabad page, where the treating haematologist can talk you through the exact schedule chosen for your case.
Because follicular maintenance uses an anti-CD20 antibody rather than intensive chemotherapy, most people tolerate it well and continue normal daily life. The main considerations are infusion-related reactions (usually mild and managed at the first doses) and a modest increase in infection risk, because the antibody lowers healthy B cells for a time. Some people notice fatigue around infusions. CION monitors blood counts and immunoglobulin levels through the maintenance period and gives clear advice on infection precautions and vaccination timing. If you would like to know what an infusion visit is actually like, read what to expect during an infusion. Report any fever promptly.
Because follicular lymphoma is a relapsing-remitting disease, some people do see it return during or after the maintenance period — and there is a well-defined pathway when that happens. The team reconfirms the disease (often with repeat imaging and sometimes a fresh biopsy), then chooses the next step based on how and when it relapsed. Options can include a different systemic therapy, radiation to a limited site, or referral for more advanced approaches. Read our relapsed or refractory lymphoma pathway, and for advanced cellular options that CION coordinates through accredited partner facilities, see CAR T-cell therapy and stem cell transplant.
No. Maintenance is considered only for people who have received induction treatment and reached a good remission — not for everyone with the diagnosis. Many people with early-stage or low-burden follicular lymphoma are safely managed with active monitoring (watch-and-wait) and do not need maintenance at all. The decision balances how you responded to induction, your risk features, your general health and your own preferences. This is exactly the kind of finely balanced call that benefits from a specialist review. You can book a free consultation with CION's haematology team, or read more on our lymphoma hub.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.